Abcellera Biologics Inc ABCL

$11.12 -1.15 (-9.37%)

Valuation

Market cap
3,762,117,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,036,600
Avg volume
4,729,820
Day's range
$11.05 – $12.33
Shares out
306,611,000
Stochastic %K
2%
Beta
1.41
Analysts
Strong Buy
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

GlobalTradersAcademy Nov 3, 7:55 AM
Off-exchange trading in $ABCL ran below normal, about 0.7x its usual pace. Big money was quieter than usual off the exchanges; the full read has the levels and the institutional holders. How it compares with the last few sessions, and what options did the same day: https://globaltradersacademy.com/articles/dark-pool-check-abcellera-biologics-abcl?utm_source=stocktwits&utm_medium=social
0 replies
Buying_Low_Selling_High Nov 2, 9:05 PM
$ABCL Stupidity has no limits. Dont panic you are holding GOLD
1 replies
Stocktradesmoon Nov 2, 8:59 PM
$ABCL I'm still here and therefore the party has not even started . $ABCL us longs are not concerned with such short term price action. Zoom out YTD. I'll stay here much longer.
0 replies
DeMampCamp Nov 2, 8:54 PM
$ABCL There's no way to spin being down almost -9% on the day with zero reasoning! Stupid ass mid terms need to hurry tf up already! For those of you that need more shares then it's a fantastic day I suppose, I don't need more, I would prefer my invest go up, not down!
0 replies
Odoji Nov 2, 8:13 PM
$ABCL 💉
0 replies
lustiger Nov 2, 7:44 PM
$ABCL 75 more shares. 20.200 now and adding.
2 replies
erpy Nov 2, 6:39 PM
$ABCL ill admit went shopping again today. Got my favorite abcl cereal. Lol.
0 replies
Stocktradesmoon Nov 2, 6:30 PM
$ABCL 🔥Jp Morgan, UBS, and Goldman target prices for $ABCL: $18, $17, and $13 and Jefferies at $21. 🙌 Today you have the chance to buy at $11.X Close to the same price at which Andrew Booth bought 37,200 shares, Michael Hayden bought over $1M worth, and John Montalbano another $110K 🤓 💡When the CFO and several board members buy over $1.5M out of their own pockets after learning about some spectacular clinical data, and the market gives you the chance to fish in the same river... You guys decide for yourselves...
0 replies